WELL Health and HEALWELL Announce Competition Bureau Has Concluded Its Merger Review and Issued a No Action Letter

WELL’s acquisition of HEALWELL clears regulatory review, removing a key uncertainty.

What the company is saying

WELL Health Technologies Corp. and HEALWELL AI Inc. announce that the Competition Bureau has concluded its review of WELL’s acquisition of a majority interest in HEALWELL and issued a No Action Letter on October 22, 2026. The company frames this as the final regulatory milestone for a transaction completed on April 1, 2025, which also included HEALWELL’s acquisition of Orion Health. WELL and HEALWELL emphasize their cooperation with the Bureau, highlighting transparency and engagement throughout the process. Hamed Shahbazi, Founder, Chairman, and CEO of WELL, expresses satisfaction with the outcome and reiterates a focus on executing strategy and delivering value to stakeholders. The announcement positions WELL as Canada’s largest outpatient healthcare company, operating 275 clinics and supporting over 5 million annual patient visits. The company highlights its technology-enabled healthcare solutions, including electronic medical records, AI-powered tools, and cybersecurity services through its WELLSTAR and CYBERWELL subsidiaries. The tone is confident, focusing on regulatory clearance and operational scale, while omitting financial performance or integration details.

What the data suggests

The Competition Bureau’s No Action Letter, issued October 22, 2026, confirms that no application will be made under section 92 of the Competition Act regarding WELL’s controlling acquisition of HEALWELL, completed April 1, 2025. The review included scrutiny of HEALWELL’s concurrent acquisition of Orion Health and required a Federal Court order for record production in December 2025. WELL and HEALWELL complied with all information requests. WELL reports operating 275 clinics in Canada and supporting more than 5 million annual patient visits, demonstrating significant operational scale. The announcement provides no financial figures, integration progress, or synergy realization data. All disclosed facts pertain to regulatory process completion and operational footprint, not financial trajectory. The evidence supports that regulatory risk is now removed, but does not substantiate any operational or financial upside from the transaction.

Analysis

The announcement is a factual regulatory update confirming the conclusion of the Competition Bureau's review and the issuance of a No Action Letter regarding WELL's acquisition of HEALWELL. The majority of claims are realised and supported by specific dates and operational figures (e.g., 275 clinics, 5 million annual patient visits). Only one minor forward-looking statement is present, which is generic and not tied to any specific financial or operational projection. There is no promotional or exaggerated language regarding future benefits, and no new capital outlay is disclosed in this update. The tone is positive but proportionate to the regulatory milestone achieved. No claims are made about imminent financial or operational upside resulting from this event.

Risk flags

• ●Integration risk remains, as the announcement provides no detail on how WELL and HEALWELL will combine operations or realize synergies following the acquisition. Without integration milestones or financial targets, investors cannot assess execution effectiveness.
• ●Financial performance risk is present, since the company discloses no revenue, profit, or cost figures related to the transaction or the acquired businesses. The absence of quantified financial outcomes leaves the impact of the acquisition on earnings or margins unknown.
• ●Disclosure risk is evident, as the announcement omits any discussion of post-acquisition performance, integration challenges, or realized benefits. Investors lack visibility into whether the transaction is delivering on strategic or financial objectives.

Bottom line

WELL Health Technologies Corp. and HEALWELL AI Inc. have removed a major regulatory overhang with the Competition Bureau’s No Action Letter, confirming no challenge to WELL’s controlling acquisition of HEALWELL and the concurrent Orion Health deal. This outcome eliminates regulatory uncertainty and allows management to focus on integration and execution. WELL’s operational scale is significant, with 275 clinics and over 5 million annual patient visits, but the announcement does not address financial performance, integration progress, or synergy realization. Investors now need to see concrete updates on how the acquisition is impacting financial results and operational efficiency. The key takeaway is that regulatory risk is resolved, but the value creation case for the transaction remains to be demonstrated through future disclosures.

Announcement summary

(TSX:WELL) (OTCQX:WHTCF) (TSX:AIDX) WELL Health Technologies Corp. and (TSX:AIDX) HEALWELL AI Inc. announced that the Commissioner of Competition has concluded the Competition Bureau's review of WELL's acquisition of a majority interest in HEALWELL and has issued a No Action Letter. The No Action Letter was issued on October 22, 2026, confirming that the Commissioner does not, at this time, intend to make an application under section 92 of the Competition Act regarding WELL's acquisition of a controlling interest in HEALWELL, which was completed on April 1, 2025. The Transaction also included HEALWELL's concurrent acquisition of Orion Health. In December 2025, the Competition Bureau announced that it had obtained a Federal Court order for the production of records and information relating to the Transaction. WELL and HEALWELL cooperated with the Bureau throughout its review and produced the requested records and information. Hamed Shahbazi, Founder, Chairman, and CEO of WELL, stated that the company is pleased with the conclusion of the review and the issuance of the No Action Letter, and that WELL remains focused on executing its strategy and delivering value to healthcare practitioners, patients, and shareholders. WELL Health Technologies Corp. is described as Canada's largest outpatient healthcare company and a leading provider of technology-enabled healthcare solutions. WELL owns and operates 275 clinics in Canada, supporting more than 5 million annual patient visits. Through its subsidiary WELLSTAR, WELL provides electronic medical records, AI-powered clinical tools, patient engagement platforms, and IT management services. WELL also provides cybersecurity services through its CYBERWELL subsidiary. HEALWELL AI is described as a healthcare artificial intelligence company focused on preventative care, developing and acquiring technology and clinical science capabilities, including data science, AI-powered patient identification, and clinical decision support.

Disagree with this article?